(Q51070419)

28 March 2018

title

Efficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma. (English)

1 reference

28 March 2018

0 references

0 references

Emmanuel Nony

6

0 references

Didier Betbeder

object named as

Didier Betbeder

5

0 references

author name string

Sophie Tourdot

1

1 reference

28 March 2018

Sabi Airouche

2

1 reference

28 March 2018

Nathalie Berjont

3

1 reference

28 March 2018

Hélène Moussu

4

1 reference

28 March 2018

Véronique Bordas-Le Floch

7

1 reference

28 March 2018

Véronique Baron-Bodo

8

1 reference

28 March 2018

Laurent Mascarell

9

1 reference

28 March 2018

Philippe Moingeon

10

1 reference

28 March 2018

language of work or name

English

0 references

publication date

10 April 2013

1 reference

28 March 2018

published in

Vaccine

1 reference

28 March 2018

volume

31

1 reference

28 March 2018

issue

23

1 reference

28 March 2018

page(s)

2628-2637

1 reference

28 March 2018

PROPHYLACTIC INOCULATION AGAINST HAY FEVER

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

The future of antigen-specific immunotherapy of allergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

CD28/CTLA-4--CD80/CD86 and ICOS--B7RP-1 costimulatory pathway in bronchial asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Standardization of allergen products: 1. Detailed characterization of GMP-produced recombinant Bet v 1.0101 as biological reference preparation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Adjuvants and vector systems for allergy vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Evaluation of therapeutic sublingual vaccines in a murine model of chronic house dust mite allergic airway inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Comparison of aerosol and intranasal challenge in a mouse model of allergic airway inflammation and hyperresponsiveness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Oral macrophage-like cells play a key role in tolerance induction following sublingual immunotherapy of asthmatic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Local immunological mechanisms of sublingual immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Inbred strain variation in lung function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Dose translation from animal to human studies revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Building better mouse models of asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Animal models of asthma: value, limitations and opportunities for alternative approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Effects of birch pollen and traffic particulate matter on Th2 cytokines, immunoglobulin E levels and bronchial hyper-responsiveness in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant bet v 1, the major birch pollen allergen, in a murine model of type I allergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Mucosal tolerance induction with hypoallergenic molecules in a murine model of allergic asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

The role of Foxp3+ T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

Local nasal immunotherapy: efficacy of Dermatophagoides farinae-chitosan vaccine in murine asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.041

10.1016/J.VACCINE.2013.03.041

7 January 2021

Identifiers

DOI

1 reference

28 March 2018

PubMed ID

23583462

1 reference

28 March 2018